This review summarizes current advances in metal-ion-mediated cGAS-STING activation and examines how metal ions and metallic nanostructures integrate agonist delivery, intrinsic pathway activation, and tumor microenvironment modulation.
Abstract
The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway represents a pivotal innate immune signaling axis that bridges cytosolic DNA sensing with type I interferon and pro-inflammatory cytokine production. However, the clinical translation of STING agonists, particularly cyclic dinucleotides (CDNs), is limited by poor membrane permeability, rapid enzymatic degradation, unfavorable pharmacokinetics, and dose-limiting systemic toxicity. Metallic nanomaterials have emerged as versatile platforms for overcoming these barriers because their coordination chemistry and tunable physicochemical properties enable the efficient loading, stabilization, and cytosolic delivery of CDNs and other STING agonists. Beyond serving as delivery vehicles, metallic nanomaterials can actively regulate cGAS-STING signaling through controlled ion release, redox reactions, catalytic generation of reactive oxygen species, and induction of nuclear or mitochondrial DNA damage. Selected metal ions, such as Mn2+ and Zn2+, may further potentiate pathway activation by modulating cGAS activity, cGAMP synthesis, STING responsiveness, or downstream signaling. This review summarizes current advances in metal-ion-mediated cGAS-STING activation and examines how metal ions and metallic nanostructures integrate agonist delivery, intrinsic pathway activation, and tumor microenvironment modulation. By linking nanoscale material design with innate immune signaling, we highlight emerging principles, translational challenges, and opportunities for developing next-generation metallic nanomaterials for cGAS-STING-based cancer immunotherapy.
The cyclic GMP-AMP synthase - stimulator of interferon genes (cGAS-STING) innate immune pathway is an intriguing, but still challenging, target for cancer immunotherapy. The current small molecule STING agonists have several limitations, such as low membrane permeability, rapid enzymatic degradation, lack of tumor accu...
Mn
2+
has emerged as a potent immunostimulatory modulator capable of activating cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) and other innate immune signaling pathways. Consequently, Mn
2+
induces type I interferon responses, and promotes robust antitumor and antiviral immunity. Recent...
Activation of the stimulator of interferon genes (STING) pathway represents a promising strategy for cancer immunotherapy. However, clinical translation of STING agonists has been hampered by inefficient intracellular delivery and compensatory upregulation of the negative feedback immune checkpoint molecule of programm...
W. You, Fan Gao, Hai-Li Wang et al.· Bioactive Materials· 0 citations
ABSTRACT STING agonists (e.g., cGAMP), which function as immunotherapeutic agents activating the stimulator of interferon genes (STING) pathway, hold promise for treating pediatric solid tumors including neuroblastoma. However, their clinical translation is hindered by limitations including burst release, short half‐li...
Yu-Bin He, Xiao Lu, Chang-Qing Yang et al.· Advancement of science· 0 citations
In vivo studies of both anti-PD-L1-responsive and resistant tumor models demonstrated that intratumoral delivery of bPEI-Thy/siPD-L1 NCs substantially reduced tumor growth and metastatic spread, induced apoptosis, alleviated immunosuppression, and extended survival.
Li-Qing Chen, Mong-Hsiu Song, Ming-Ji Jin et al.· Journal of Controlled Releas...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.